Cleveland Clinic’s top 10 medical innovations for 2020

Amy Baxter | | Health Exec | Management

Cleveland Clinic, a Cleveland-based non-profit academic medical center that has frequently landed among the top-ranked hospitals, has released its rankings for the best medical innovations for 2020.

The healthcare provider announced the list at the 2019 Medical Innovation Summit this week, organized by the developmental and commercialization arm of the operator, Cleveland Clinic Innovations. The list names innovations that will enhance healing and change healthcare in 2020, and was selected by a panel of doctors and researchers led by Michael Roizen, MD, emeritus chief wellness officer at Cleveland Clinic.

“Healthcare is ever-changing, and we anticipate that these innovations will significantly transform the medical field and improve care for patients at Cleveland Clinic and throughout the world,” Roizen said.

Here are the top 10 medical innovations:

  1. Dual-acting osteoporosis drug (romosozumab)
  2. Expanded use of minimally invasive mitral valve surgery
  3. Inaugural medication for transthyretin amyloid cariomyopathy
  4. Therapy for mitigation of peanut allergies
  5. Closed-loop spinal cord stimulation
  6. Biologics in orthopaedic repair
  7. Antibiotic envelope for cardiac implantable device infection prevention
  8. Bempedoic acid for cholesterol lowering in statin intolerant patients
  9. PARP inhibitors for maintenance therapy in ovarian cancer
  10. Drugs for heart failure with preserved ejection fraction

Cleveland Clinic also recently announced a new digital health company called The Clinic with telehealth company American Well.

See the full list here.

Amy Baxter
Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Related Content

FDA issues Class I recall on counterfeit infusion pump batteries
FDA issues alert on PCNL sheath safety after patient death
Bipartisan bills in Congress would force insurance companies, PBMs to sell pharmacies
Anthem BCBS reverses course on anesthesia time limits
FDA issues Class I recall on insulin syringes due to risk of death
FDA issues Class I recall on insertion tubes after manufacturing error

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.